Quanterix Publishes Landmark Study on Personalized MS Monitoring Using Dual GFAP/NfL Blood Test Approach.

Quanterix announces a landmark study demonstrating the use of a dual blood test approach for multiple sclerosis (MS) monitoring. The study, published in the journal Brain, validates the use of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) serum biomarkers for predicting relapse and chronic disability progression in MS. The study found that elevated GFAP levels were associated with a higher risk of progression independent of relapse activity, while NfL levels were associated with an increased risk of relapses. The use of extensive Simoa-based normative reference databases for both biomarkers enables clinicians to translate test results into meaningful clinical action for individual patients.